Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy.
OBJECTIVE
The treatment of FIGO stage IB2 cervical cancer is controversial. Our aim was to assess treatment patterns, outcomes, and complications in patients with stage IB2 cervical cancer.


METHODS
A retrospective study of patients with stage IB2 cervical carcinoma at a single institution between January 1982 and September 2006 was performed. To adequately control treatment variables, we only included patients who underwent their entire treatment at our institution. Toxicity was assessed using NCI Common Toxicity Criteria (CTC).


RESULTS
We identified 82 patients, of whom 47 met the strict inclusion criteria. Of these, 27 patients (57%) underwent primary radical hysterectomy (RH) and 20 (43%) were treated with definitive radiation/chemoradiation therapy (RT/CRT). Patients selected for RT/CRT had a higher American Society of Anesthesiologist (ASA) score than those selected for surgery (P=0.037). The 3-year progression free survival rate was 52% for the RH group and 55% for the RT/CRT group (P=0.977). The 3-year overall survival rates were 72% and 55%, respectively (P=0.161). Overall, 52% of patients in the RH group received postoperative radiation therapy as part of their adjuvant treatment. CTC grade 3, 4, and 5 complications affected 5 patients (19%) in the RH group and 3 (15%) in the RT/CRT group.


CONCLUSIONS
Both RH and definitive RT/CRT are adequate management strategies for patients with FIGO stage IB2 cervical cancer. However, there was a subset of patients in whom RH as monotherapy was appropriate. Further studies are needed to evaluate the role of new preoperative models that will accurately identify these patients.
Zivanovic
Oliver
O
Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Alektiar
Kaled M
KM
Sonoda
Yukio
Y
Zhou
Qin
Q
Iasonos
Alexia
A
Tew
William P
WP
Diaz
John P
JP
Chi
Dennis S
DS
Barakat
Richard R
RR
Abu-Rustum
Nadeem R
NR
D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D055815:Young Adult
Obstet Gynecol. 1974 Aug;44(2):265-72
4417035
Gynecol Oncol. 1989 Dec;35(3):314-20
2599466
Int J Gynecol Cancer. 2006 May-Jun;16(3):1147-51
16803498
J Reprod Med. 2005 Jul;50(7):486-90
16130844
Lancet. 1997 Aug 23;350(9077):535-40
9284774
Gynecol Oncol. 1999 May;73(2):177-83
10329031
Cancer. 1989 Jun 1;63(11):2220-3
2720571
Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):9-16
8175451
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Surg Gynecol Obstet. 1980 Apr;150(4):529-31
7361240
Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):605-13
9486610
Obstet Gynecol. 1975 Nov;46(5):507-10
1196552
Am J Obstet Gynecol. 1976 Dec 1;126(7):785-98
998673
Gynecol Oncol. 1983 Feb;15(1):42-7
6401639
J Clin Oncol. 2000 Apr;18(8):1740-7
10764435
J Clin Oncol. 2000 Apr;18(8):1606-13
10764420
N Engl J Med. 1999 Apr 15;340(15):1154-61
10202166
Cancer. 1991 Jul 15;68(2):272-7
2070325
Cancer. 1992 Jun 1;69(11):2796-806
1571911
Gynecol Oncol. 1996 Apr;61(1):3-10
8626113
Gynecol Oncol. 2003 Jun;89(3):343-53
12798694
Int J Cancer. 2001 Oct 15;94(2):153-6
11668491
Gynecol Oncol. 1989 Apr;33(1):34-9
2703164
Int J Gynecol Cancer. 2007 Jan-Feb;17(1):132-6
17291243
Gynecol Oncol. 2007 Dec;107(3):532-40
17900674
J Am Coll Surg. 1996 Oct;183(4):393-400
8843270